Infectious Diseases Society of America guidelines on COVID-19 (search done on 4 April 2020)

Added September 8, 2020

Citation: Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clinical Infectious Diseases. 2020 Apr 27:ciaa478.

What is this? A variety of therapies have been suggested as treatments for patients with COVID-19.

In the systematic review prepared for a guideline from the Infectious Diseases Society of America, the authors searched for studies of the treatment of COVID-19 patients. They did not restrict their searches by type or language of publication and searched for articles published from 1 January 2019 to 4 April 2020. The guideline panel used 13 studies as the evidence base for their recommendations.

What was found: Based on the evidence in the review, the guideline panel recommended that for patients who had been admitted to hospital with COVID-19, hydroxychloroquine/chloroquine should be used in the context of a clinical trial.

Based on the evidence in the review, the guideline panel recommended that for patients who had been admitted to hospital with COVID-19, hydroxychloroquine/chloroquine plus azithromycin should only be used in the context of a clinical trial.

Based on the evidence in the review, the guideline panel recommended that for patients who had been admitted to hospital with COVID-19, lopinavir/ritonavir should only be used in the context of a clinical trial.

Based on the evidence in the review, the guideline panel suggest against the use of corticosteroid for patients who had been admitted to hospital with COVID-19 pneumonia.

Based on the evidence in the review, the guideline panel recommended that for patients who had been admitted to hospital with acute respiratory distress syndrome (ARDS) due to COVID-19, corticosteroids should be used in the context of a clinical trial.

Based on the evidence in the review, the guideline panel recommended that for patients who had been admitted to hospital with COVID-19, tocilizumab should only be used in the context of a clinical trial.

Based on the evidence in the review, the guideline panel recommended that for patients who had been admitted to hospital with COVID-19, COVID-19 convalescent plasma should be used in the context of a clinical trial.

 

Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.

Share